Brief Article
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2014; 20(8): 2107-2112
Published online Feb 28, 2014. doi: 10.3748/wjg.v20.i8.2107
Table 1 Patient demographics and baseline characteristics n (%)
Treatment (n = 90)Control (n = 30)P-value
Age (yr)52.7 ± 10.158.3 ± 12.5< 0.0011
Gender
Male36 (40.0)14 (46.7)0.573
Female54 (60.0)16 (53.3)
Baseline HCV RNA level (log10 copies/mL)5.30 ± 1.185.23 ± 1.150.681
Baseline MELD score12.6 (9.8, 15.2)12.5 (9.4, 15.8)0.654
Baseline Child-Pugh score9.0 (7.0, 10.0)8.0 (7.0, 10.0)0.809
Total bilirubin (mg/dL)
< 29 (10.0)5 (16.67)0.691
2-340 (44.4)12 (40.0)
> 341 (45.6)13 (43.33)
Serum albumin (g/dL)
> 3.59 (10.0)3 (10.0)0.0051
2.8-3.540 (44.4)19 (63.3)
< 2.841 (45.6)8 (26.7)
Prothrombin time INR
< 1.726 (28.9)8 (26.7)0.0291
1.7-2.350 (55.6)13 (43.3)
> 2.314 (15.5)9 (30.0)
Hepatic encephalopathy
None90 (100.0)30 (100.0)NA
Ascites
Absent90 (100.0)26 (87.4)< 0.0011
Easily controlled0 (0.0)4 (13.3)
Table 2 Changes in hepatic phosphomonoester to phosphodiester ratio before antiviral therapy and 6 mo after the start of antiviral therapy
Child AChild BChild C
Before therapy0.20 ± 0.170.27 ± 0.240.39 ± 0.18
Six mo after the start of therapy0.16 ± 0.090.19 ± 0.120.22 ± 0.16
P> 0.05< 0.05< 0.05
Table 3 Changes in hepatic phosphomonoester to phosphodiester ratio in virological responders and nonresponders after antiviral treatment n (%)
Patient groupPME/PDE decreasedPME/PDE unchangedPME/PDE increased
Responders (n = 69)54 (78)9 (13)6 (9)
Nonresponders (n = 21)2 (10)4 (20)15 (70)
P> 0.05< 0.05< 0.05